BioCentury
ARTICLE | Company News

Allergan in deals with Lysosomal Therapeutics, Assembly

January 10, 2017 12:30 AM UTC

Allergan plc (NYSE:AGN) announced two deals Monday, gaining an exclusive option to acquire neurodegenerative disease company Lysosomal Therapeutics Inc. (Cambridge, Mass.) and a license for rights to four gastrointestinal microbiome programs from Assembly BioSciences Inc. (NASDAQ:ASMB).

Allergan purchased an option to acquire Lysosomal when a planned Phase Ib trial of its lead program is completed. The preclinical program, LTI-291, is designed to stimulate activity of glucocerebrosidase (GBA; GCase) in the brain to treat Parkinson’s disease. Financial terms of the deal are undisclosed. Lysosomal will also receive R&D funding from Allergan...